Navigation Links
New data show patients using avonex reported less sick leave and short-term disability costs
Date:6/2/2008

Denver, CO June 2, 2008 Results from an analysis assessing the differences in health benefits costs (HBCs) and lost time among employees suffering from multiple sclerosis (MS) being treated with injectable disease modifying therapies (DMTs) were presented and announced by Biogen Idec as poster presentations at the Consortium of Multiple Sclerosis Center (CMSC) annual meeting in Denver, Colorado, May 28-May 31, 2008. The results revealed that patients treated with AVONEX (interferon beta-1a IM) reported significantly less sick leave, sick leave costs and short-term disability costs than patients treated with Copaxone (glatiramer acetate).

"It is clear that a key priority in the treatment of MS is for patients to maintain a sense of normalcy," said Richard Brook, Head, Retrospective Analysis, JeSTARx Group and a study author. "Data from this study show that patients taking AVONEX miss less work due to sick leave compared to patients taking Copaxone, helping to maintain their lifestyle. Also, patients taking AVONEX saved sick leave costs and short-term disability costs for their employers and healthcare insurers compared to Copaxone."

The study analyzed an integrated employer dataset of U.S. employees from 2001-2007 to gather HBCs and lost work time from the Human Capital Management Services (HCMS) Research Reference database. HCMS receives information on all employees' short- and long-term-disability claims, workers' compensation claims, and sick-leave claims (both time and salary replacement costs). The database also contains employee-specific information on demographics, company type, job type, employment status, salary, co-pays, deductibles, and health plan. The HCMS database is representative of the general U.S. workforce in terms of age and gender; however the salaries tended to be higher than the general U.S. workforce. This study included only MS patients that were employed at the time of analysis.

The HBC portion of the study data involved a total of 311 employees and showed that among the four DMTs:

  • AVONEX patients reported low total sick leave (SL) and short-term disability (STD) costs;
  • Copaxone patients had significantly higher SL ($969 vs. $523) (P<0.05) and STD ($1056 vs. $87) (P<0.05) costs than AVONEX

The absentee portion of the study data involved a total of 273 employees and showed that among the four DMTs:

  • AVONEX patients reported 42 percent less sick leave than Copaxone (2.98 days/year vs. 7.18 days/year; P≤0.01)

About the Study

Records of 785 patients with MS were extracted from the database. Available data was obtained from the 311 patients on a DMT: (IFN-1a IM (AVONEX) n = 156, IFNβ-1b (Betaseron) n = 55, glatiramer acetate (Copaxone) n = 87, or IFN-1a SC (Rebif) n =13), and were followed for one year after their initial prescription. Two-part regression modeling was used to determine the annual cost differences (in 2007 USD) and annual lost time (in days) between cohorts while controlling for demographics, job-related information, geography, and Charlson Comorbidity Index.

"Such reductions in sick leave days, sick leave costs and short-term disability related costs reinforce the real-life benefits and proven clinical efficacy of AVONEX," said Dr. Kitty Rajagopalan, director of Global Health Economics, Biogen Idec. "We pride ourselves on providing a treatment that is not only efficacious, but allows our patients to live a normal life that includes the ability to consistently attend work. Therefore this is an important addition to the body of evidence that demonstrates the impact of MS on patients and the importance of treating appropriately."


'/>"/>

Contact: Kathleen Vigneault
kathleen.vigneault@mslpr.com
617-937-2546
Manning Selvage & Lee
Source:Eurekalert

Related medicine news :

1. IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE)
2. First study to examine vitamin D insufficiency in pediatric patients with low bone density
3. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
4. Anemia Drugs May Speed Tumor Growth in Some Cancer Patients
5. New combination therapy safe, promising for melanoma patients
6. Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients
7. Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection
8. Drug may prolong organ life in noncompliant kidney transplant patients
9. Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s
10. Black patients with terminal cancer more likely to choose aggressive care at end of life
11. Study suggests chemotherapy diminishes fertility in breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: